Back
Compare AU
Compare DRUG vs. LNAS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DRUG and LNAS. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | LNAS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 75 | 72 |
Median incremental investment | $742.79 | $1,003.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,810.48 | $4,227.73 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | LNAS | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | LNAS.AX was created on 2020-07-13 by ETFS. The fund's investment portfolio concentrates primarily on large cap equity. Global X Ultra Long Nasdaq 100 Complex ETF (ASX Code: LNAS.AX) is an exchange traded managed fund that aims to provide investors with geared returns that are positively related to the returns of the Nasdaq-100 Index. The fund provides exposure to the Nasdaq-100 Index of between 200% and 275% of its net asset value. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | Global X Ultra Long Nasdaq 100 Complex ETF (100 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | United States (96.01 %) Canada (1.41 %) Netherlands (1.08 %) |
Management fee | 0.57 % | 1 % |
Key Summary
DRUG | LNAS | |
|---|---|---|
Issuer | BetaShares | ETFS |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | NASDAQ-100 Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 1 % |
Price | $8.50 | $13.73 |
Size | $163.973 million | $66.870 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 1.92 % | 19.63 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 12/07/2020 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | LNAS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 75 | 72 |
Median incremental investment | $742.79 | $1,003.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,810.48 | $4,227.73 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | LNAS | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | LNAS |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |